Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology

@article{Barnes2011EvidencebasedGF,
  title={Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology},
  author={Thomas R. E. Barnes},
  journal={Journal of Psychopharmacology},
  year={2011},
  volume={25},
  pages={567 - 620}
}
  • T. Barnes
  • Published 3 February 2011
  • Medicine, Psychology
  • Journal of Psychopharmacology
These guidelines from the British Association for Psychopharmacology address the scope and targets of pharmacological treatment for schizophrenia. A consensus meeting, involving experts in schizophrenia and its treatment, reviewed key areas and considered the strength of evidence and clinical implications. The guidelines were drawn up after extensive feedback from the participants and interested parties, and cover the pharmacological management and treatment of schizophrenia across the various… 
Guidelines for the Pharmacotherapy of Schizophrenia in Adults
TLDR
There is a paucity of established evidence to guide treatment decision making in the case of clozapine-resistant schizophrenia, a subsample that represents a sizable proportion of those with schizophrenia.
Pharmacological guidelines for schizophrenia: a systematic review and comparison of recommendations for the first episode
TLDR
The quality of these guidelines using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) instrument is assessed and recommendations in relation to the key health questions that are relevant to the pharmacological treatment of first-episode schizophrenia are compared.
Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology
TLDR
These updated guidelines from the British Association for Psychopharmacology replace the original version published in 2011 and address the scope and targets of pharmacological treatment for schizophrenia, including first-episode, relapse prevention, and illness that has proved refractory to standard treatment.
A systematic review of clinical guidelines on choice, dose, and duration of antipsychotics treatment in first- and multi-episode schizophrenia
Abstract Clinical guidelines provide evidence-based recommendations to regulate pharmacological treatment of psychotic disorders. However, the quality of evidence, country of origin, and publication
BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP
TLDR
The guidelines primarily cover the pharmacological management of withdrawal, short- and long-term substitution, maintenance of abstinence and prevention of complications, where appropriate, for substance abuse or harmful use or addiction as well management in pregnancy, comorbidity with psychiatric disorders and in younger and older people.
Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology
This revision of the 2005 British Association for Psychopharmacology guidelines for the evidence-based pharmacological treatment of anxiety disorders provides an update on key steps in diagnosis and
New Targets for the Management of Schizophrenia
TLDR
The cognitive therapy, social skills, psychoeducation programs, family intervention, training programs, and case management or assertive community treatment are the major categories of psychosocial intervention which is an important part of the disease management.
More ACTIONS needed to reach a consensus on adjunctive antidepressant therapy for negative symptoms of schizophrenia
TLDR
This double-blind, placebo-controlled, parallel-group, 15-centre pragmatic trial randomised in a 1:1 ratio to receive either citalopram or placebo as an adjunctive therapy to the baseline ongoing stable dose of second generation antipsychotic treatment for 48 weeks.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 1,087 REFERENCES
BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP
TLDR
The guidelines primarily cover the pharmacological management of withdrawal, short- and long-term substitution, maintenance of abstinence and prevention of complications, where appropriate, for substance abuse or harmful use or addiction as well management in pregnancy, comorbidity with psychiatric disorders and in younger and older people.
The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.
TLDR
An extensive literature review was conducted to determine whether the current psychopharmacological treatment recommendations required revision and whether there was sufficient evidence to warrant new treatment recommendations for prespecified outcomes of interest.
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
TLDR
An extensive literature review was conducted to determine whether the current psychopharmacological treatment recommendations required revision and whether there was sufficient evidence to warrant new treatment recommendations for prespecified outcomes of interest.
Evidence-Based Guidelines for the Pharmacological Management of Substance Misuse, Addiction and Comorbidity: Recommendations from the British Association for Psychopharmacology
TLDR
These guidelines primarily cover the pharmacological management of withdrawal, shortand longterm substitution, maintenance of abstinence and prevention of complications, where appropriate, in substance misuse, addiction and comorbidity with psychiatric disorders.
Translating the psychopharmacology of antipsychotics to individualized treatment for severe mental illness: a Roadmap.
TLDR
The Roadmap recommendations provide guidance for clinicians on how to fine-tune their psychopharmacologic strategies with antipsychotics to achieve the best outcomes for each individual patient.
Determinants of medication compliance in schizophrenia: empirical and clinical findings.
TLDR
The substantive literature on medication adherence in schizophrenia is reviewed and a modified health belief model within which empirical findings can be understood is described to help inform both pharmacological and psychosocial treatment planning.
Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations.
TLDR
The PORT Treatment Recommendations provide a basis for moving toward "evidence-based" practice for schizophrenia and identify both the strengths and limitations in the current knowledge base.
The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009.
TLDR
The methods and outcomes of the update process are presented here and resulted in recommendations for 16 psychopharmacologic and 8 psychosocial treatments for schizophrenia, representing significant unmet needs in important treatment domains.
Pharmacotherapy of patients with schizophrenia and substance abuse
TLDR
Slight advantages were found for second-generation antipsychotic agents over conventional antipsychotics with regard to improvement of distinct psychopathological symptoms, reduced craving, and greater reduction of substance use in schizophrenia patients.
Remission in schizophrenia: proposed criteria and rationale for consensus.
TLDR
The first consensus-based operational criteria for symptomatic remission in schizophrenia are based on distinct thresholds for reaching and maintaining improvement, as opposed to change criteria, allowing for alignment with traditional concepts of remission in both psychiatric and nonpsychiatric illness.
...
1
2
3
4
5
...